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Abstract 
 
Glioblastoma is the most common and aggressive form of intrinsic brain tumor. Transforming 
growth factor (TGF)-β represents a central mediator of the malignant phenotype of these tumors 
by promoting invasiveness and angiogenesis, maintaining tumor cell stemness, and inducing 
profound immunosuppression. Integrins, which are highly expressed in glioma cells, interact with 
the TGF-β pathway. Furthermore, a link has been described between activity of the transcription 
factor aryl hydrocarbon receptor (AhR) and TGF-β expression.  
Here we demonstrate that integrin inhibition, using αv, β3 or β5 neutralizing antibodies, RNA 
interference-mediated integrin gene silencing or pharmacological inhibition by the cyclic RGD 
peptide EMD 121974 (cilengitide) or the non-peptidic molecule GLPG0187, inhibits AhR activity. 
These effects are independent of cell detachment or cell density. While AhR mRNA expression 
was not affected by integrin inhibition, AhR total and nuclear protein levels were reduced, 
suggesting that integrin inhibition-mediated regulation of AhR may occur at a posttranscriptional 
level. AhR-null astrocytes, AhR-null hepatocytes, or glioblastoma cells with a transiently silenced 
AhR gene showed reduced sensitivity to integrin inhibition-mediated alterations in TGF-β 
signaling indicating that AhR mediates integrin control of the TGF-β pathway. Accordingly, there 
was a significant correlation of αv integrin levels with nuclear AhR and pSmad2 levels as 
determined by immunohistochemistry in human glioblastoma in vivo. 
In summary, this study identifies a signaling network comprising integrins, AhR and TGF-β and 
validates integrin inhibition as a promising strategy not only to inhibit angiogenesis, but also to 
block AhR- and TGF--controlled features of malignancy in human glioblastoma. 
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Introduction 
 
The aryl hydrocarbon receptor (AhR) belongs to the family of basic helix-loop-
helix/Per/ARNT/Sim (PAS) transcription factors and is the only member known to be activated 
by a ligand. In addition to the over 400 exogenous ligands, among them polycyclic aromatic 
hydrocarbons (PAH) and dioxins, endogenous AhR ligands such as tryptophan derivatives have 
been identified (1, 2). In the absence of ligand, AhR is present in the cytoplasm, bound to 
several molecular chaperone proteins including heat shock protein 90 (HSP90), the AhR-
interacting protein (AIP) and the co-chaperone p23, maintaining an inactive state. Ligand binding 
induces a conformational change of AhR, resulting in its nuclear translocation by release of the 
chaperone complex and heterodimerization with AhR nuclear translocator (ARNT). The 
AhR/ARNT complex binds to its binding motif, the dioxin responsive elements (DRE), present in 
the promoter of target genes like CYP1A1 that is coding for a xenobiotic-metabolizing enzyme 
(3). In addition to this canonical signaling, several non-canonical signaling pathways have been 
described for AhR such as its direct association with the hyperphosphorylated retinoblastoma 
protein (pRB) which induces G1-cell cycle arrest or its action as a ligand-dependent E3 ubiquitin 
ligase mediating polyubiquitination (4). Beside its critical role in xenobiotic-induced toxicity and 
carcinogenesis, AhR regulates multiple processes such as cellular proliferation and 
differentiation, tumor development and progression as well as cell motility and migration under 
physiological conditions, too (5). Depending on the tumor type, AhR may exhibit tumor 
suppressive or oncogenic activity (6). Human gliomas produce kynurenine (Kyn), an 
endogenous ligand generated via tryptophan-2,3-dioxygenase (TDO), which activates the AhR 
pathway, thus leading to tumor progression and poor survival (7). Moreover, inhibition of AhR 
signaling results in reduced proliferation, clonogenicity, invasiveness and transforming growth 
factor (TGF)-β signaling in human glioma cell lines (8). TGF-β is a central mediator of the 
malignant phenotype of gliomas that promotes growth, invasiveness, angiogenesis as well as 
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stemness and contributes to the immune evasion of these tumors (9, 10). Recently, we have 
shown that inhibition of αv integrins reduces TGF-β expression and down-stream signaling (11). 
Integrins are cell surface receptors formed by the combination of 18 α and 8 β subunits that play 
important and diverse roles in many biological processes such as cell adhesion, migration, 
invasion, survival and angiogenesis. Moreover, certain integrins are overexpressed in tumor 
cells as well as tumor-associated host cells and may have a profound role in tumor progression 
(12). AhR in turn may regulate the composition of integrin receptors on the cell surface and 
signaling of focal adhesion kinase (FAK), a non-receptor protein tyrosine kinase involved in 
integrin signaling cascades (5, 13, 14). Here, we aimed at defining a possible interplay of 
integrins and AhR in the regulation of TGF-β signaling in glioblastoma. 
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Results 
 
Integrin inhibition reduces AhR activity in human glioma cells 
In order to analyze whether integrin inhibition interferes with AhR signaling, we first assessed a 
bona fide target of AhR, that is, CYP1A1 (15). LN-308 cells were transiently transfected with the 
CYP1A1 reporter construct (DRE). Pharmacological integrin inhibition using cilengitide or 
GLPG0187 significantly reduced DRE reporter activity in a concentration-dependent manner. 
The AhR receptor antagonist CH-223191 was used as a positive control (Fig. 1A,B). Similarly, 
exposure to antibodies neutralizing different αv integrins decreased DRE reporter activity 
confirming the assumption that integrin inhibition interferes with AhR activity (Fig. 1C). These 
findings were further corroborated using RNA interference to specifically silence single αv-
integrins. As shown before, exposure to integrin-specifc siRNA molecules resulted in reduced 
expression of the targeted integrin in LN-308 glioma cells (11). Integrin gene silencing was 
paralleled by a significant reduction of DRE reporter activity (Fig. 1D). Next we asked whether 
integrin inhibition-induced cell detachment interferes with AhR signaling (16). For this purpose, 
we separately analyzed the attached and floating fractions of LN-308 cells upon integrin 
inhibition. AhR signaling was reduced to a similar extent in both cell fractions, indicating that the 
observed effects occur independently of cell detachment. CH-223191 and the AhR agonist 3-
methylcholanthrene (3-MC) were used as controls (Fig. 1E). Moreover, LN-229 cells, which do 
not detach or die upon integrin inhibition (16), also displayed reduced DRE reporter activity in 
response to integrin inhibition (Fig. 1F). To further confirm the hypothesis that integrin inhibition 
interferes with AhR signaling, mRNA levels of the AhR-responsive gene, CYP1A1, were 
determined. Pharmacological integrin inhibition resulted in strongly reduced CYP1A1 mRNA 
levels while exposure to CH-223191 or 3-MC reduced or increased CYP1A1 mRNA expression, 
respectively (Fig. 1G). Time course analyses demonstrated a reduction of CYP1A1 mRNA levels 
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within 48 h following integrin inhibition (Fig. 1H). In line with these findings, a dramatic reduction 
of CYP1A1 expression levels was observed when cells were treated with specific anti-αv integrin 
antibodies (Fig. 1I). Additionally, integrin gene silencing by RNA interference reduced the 
expression of CYP1A1, confirming the link between integrin signaling and AhR expression (Fig. 
1J).  
Because of their potential contribution to therapy resistance, we assessed the interaction 
between integrins and AhR activity in a panel of GIC lines, too. Interference with integrin 
signaling using the pharmacological inhibitors cilengitide (Fig. 2A) or GLPG0187 (Fig. 2B) 
resulted in reduced DRE reporter activity in GIC lines. Moreover, the expression of the AhR 
target gene CYP1A1 was reduced (Fig. 2C). Accordingly, the integrin-AhR axis is also present in 
the population of glioma cells with stem cell properties. 
 
Inhibition of integrin activity reduces AhR protein levels  
Next we addressed the mechanism mediating reduced AhR signaling upon integrin inhibition. 
Integrin inhibition using pharmacological inhibitors or specific siRNA oligonucleotides did not 
alter levels of AhR transcripts (Fig. 3A). Plasmid-mediated gene transfer was used to express a 
constitutive active form of AhR (AhR-CA) in LN-229 cells. Here, the expression of AhR is 
controlled by an independent promoter. Upon exposure of LN-229 control or AhR-CA cells to 
control peptide or cilengitide, DRE reporter activity was determined. Integrin inhibition decreased 
AhR reporter activity not only in control, but also in AhR-CA cells, confirming that altered AhR 
signaling upon integrin inhibition is not mediated by transcriptional regulation (Fig. 3B, top). 
Moreover, while AhR-CA cells expressed higher mRNA levels of the target gene CYP1A1 than 
control cells, integrin inhibition reduced CYP1A1 expression in both cell lines (Fig. 3B, bottom).  
However, when we analyzed AhR protein expression upon integrin inhibition using cilengitide, 
we found a reduction in a concentration-dependent manner. Parallel activity on the TGF-β 
pathway activity was confirmed at the level of Smad2 phosphorylation (Fig. 3C). Moreover, we 
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specifically asked whether integrin inhibition interferes with AhR activation, that is, translocation 
and nuclear accumulation of AhR, too. To this end, fractionated lysates of LN-308 cells exposed 
to the control peptide RAD (cyclo-(Arg-Ala-Asp-DPhe-Val)) or cilengitide were prepared to 
determine AhR nuclear and cytoplasmic protein levels separately. Integrin inhibition strongly 
reduced nuclear AhR levels whereas the cytoplasmic levels of AhR remained unaltered (Fig. 
3D). To support these findings, we examined glioma cells by immunofluorescence for AhR 
following integrin inhibition. Here, cilengitide diminished total AhR as well as nuclear AhR levels 
(Fig. 3E) confirming the influence of integrin activity on AhR protein levels. 
 
Integrin-mediated control of the TGF-β pathway is abrogated by AhR gene silencing 
Based on the findings that integrin inhibition interferes with TGF-β signaling (11) and that AhR 
controls the TGF-β pathway in human glioma cells (8), we asked whether integrin inhibition-
mediated effects on TGF-β signaling are promoted by AhR. Hence, we analyzed murine AhR+/+ 
(control) and AhR-/- (AhR-null) hepatocytes that had been isolated from wild-type or AhR-KO 
mice (17), for alterations in the TGF-β pathway upon integrin inhibition. Absence of AhR mRNA 
expression in AhR-/- cells was confirmed by real-time PCR (Fig. 4A, top). mRNA levels of the 
AhR response gene CYP1A1 were reduced compared to control cells. Moreover, exposure to 
cilengitide resulted in reduced CYP1A1 mRNA expression only in AhR+/+ hepatocytes, 
suggesting that this effect is AhR-mediated (Fig. 4A, bottom). Furthermore, integrin inhibition 
resulted in a reduction of DRE reporter activity in control, but not in AhR-/- hepatocytes (Fig. 4B). 
Finally, immunoblot analysis demonstrated that constitutive pSmad2 protein levels were similar 
in control and AhR-null hepatocytes. However, integrin inhibition reduced Smad2 
phosphorylation more efficiently in control cells than in AhR-null hepatocytes, indicating that AhR 
contributes to integrin inhibition-mediated effects on the TGF-β pathway (Fig. 4C). Based on the 
finding that murine hepatocytes detached and died upon integrin inhibition (data not shown) and 
previous work demonstrating that detachment may also affect TGF-β signaling (11, 18), we 
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extended our investigations to human HaCaT keratinocytes, with lentivirus-mediated AhR 
silencing, which neither detached nor died upon integrin inhibition (data not shown). Compared 
to control cells, AhR and CYP1A1 mRNA levels were strongly diminished in AhR-deficient 
keratinocytes. Integrin inhibition had no effect on AhR mRNA expression in control or AhRsi cells 
and a significant loss in CYP1A1 levels was detected in HaCaT control cells only (Fig. 5A). 
Expectedly, AhR protein levels were lower in AhRsi keratinocytes compared to control. Integrin 
inhibition resulted in reduced AhR protein levels in HaCaT control cells but no such effect was 
observed in HaCaT cells with silenced AhR (Fig. 5B, E). Moreover, integrin inhibition reduced 
DRE reporter activity in HaCaT control cells in a concentration-dependent manner, but not in 
AhRsi cells (Fig. 5C). Constitutive TGF-β2 mRNA levels were lower in AhRsi than in control cells, 
suggesting that TGF-β2 signaling is under control of AhR in these cells, thus making them an 
appropriate model to study the relevance of AhR for integrin inhibition-mediated interference with 
the TGF-β pathway. Cilengitide strongly reduced TGF-β2 mRNA expression in HaCaT control, 
but not in AhRsi cells, whereas no effect on TGF-β1 mRNA levels was detected (Fig. 5D). 
Accordingly, HaCaT AhRsi cells showed reduced constitutive expression of pSmad2, whereas 
integrin inhibition reduced pSmad2 levels only in HaCaT control, but not in AhRsi cells (Fig. 5E). 
 
The integrin-AhR-TGF-β signaling axis is active in cells of glial origin 
In order to investigate the relevance of the identified signaling axis in cells of glial origin, we next 
analyzed astrocytes obtained from AhR-null mice. Absence of AhR mRNA expression and a 
decrease of CYP1A1 mRNA expression were observed in AhR-null astrocytes relative to AhR-
expressing astrocytes (control). Moreover, a significant reduction of CYP1A1 expression upon 
integrin inhibition was detected only in control cells (Fig. 6A, top, middle). Again, compared with 
control cells, TGF-β2 mRNA levels were lower and sensitivity to cilengitide was lacking in AhR-
null astrocytes (Fig. 6A, bottom). TGF-β1 expression levels were at the detection limit in these 
cells (data not shown).  Finally, to proof our hypothesis in glioblastoma cells, we transiently 
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silenced AhR in LN-308 cells using RNA interference which resulted in strongly reduced AhR 
mRNA levels. Integrin inhibition did not alter AhR expression, whereas a trend towards reduced 
CYP1A1 mRNA levels was observed in control and AhRsi cells (Fig. 6B). Besides, cilengitide 
reduced AhR protein levels and DRE reporter activity in control, but not in AhRsi cells (Fig. 6C). 
Constitutive TGF-β2 mRNA expression was reduced in AhRsi cells compared to control cells and 
cilengitide strongly reduced TGF-β2 mRNA expression in control cells only. Again, TGF-β1 
mRNA levels were not affected by AhR knockdown nor by integrin inhibition, suggesting that 
control of TGF-β signaling through the AhR-integrin signaling axis is mediated primarily through 
TGF-β2 (Fig. 6D, top). AhR protein levels were reduced in LN-308 AhRsi cells compared to 
control cells and altered by integrin inhibition in control, but not in AhRsi cells. Moreover, LN-308 
AhRsi cells showed reduced constitutive pSmad2 levels whereas cilengitide inhibition reduced 
pSmad2 levels more prominently in LN-308 control than in AhRsi cells. As described previously 
(11), reductions in pSmad2 levels were paralleled by increases in total Smad2 levels, possibly 
representing a negative feedback loop (Fig. 6D, bottom).  
Finally, to confirm the relevance of the identified signaling axis in vivo, we performed correlation 
analyses using data from glioblastoma patients within The Cancer Genome Atlas (TCGA) 
database. There was a significant correlation of αv integrin and AhR expression (Fig. 7A). For 
testing these findings on the protein level, we analyzed the levels of integrin αv, AhR and 
pSmad2 by immunohistochemistry on a tissue microarray of glioblastomas. Again, αv integrin 
levels correlated with AhR levels. Moreover, a significant correlation of αv integrin with pSmad2 
protein levels was observed (Fig. 7B).  
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Discussion 
 
AhR may act as a tumor promoter by driving several malignant features such as proliferation, 
clonogenicity and invasiveness in human glioblastoma (8). Antagonism of AhR interferes with 
TGF-β pathway activity at the level of ligand expression. TGF-β is a multipotent cytokine that 
has a profound impact on the aggressive phenotype of glioblastoma (19). The TGF-β pathway, 
in turn, is controlled by the activity of αv integrins in glioma cells (11). AhR has been described 
as a regulator of the composition of integrins at the cell surface (13, 20-23), but inhibitory effects 
of AhR on FAK phosphorylation, a central mediator of integrin signaling, have also been 
observed (14, 24). These findings provided the rationale for the present study, which aimed at 
elucidating a possible link between the AhR and integrin signaling pathways in modulating the 
activity of the TGF-β pathway in glioblastoma.  
Exposure to αv, β3 or β5 neutralizing antibodies, RNA interference-mediated integrin gene 
silencing or pharmacological integrin inhibition decreased DRE reporter activity and reduced 
expression of the AhR target gene CYP1A1 in human long-term as well as glioma-initiating cell 
lines (Fig. 1, Fig. 2). Integrin inhibition induces detachment of some human glioma cells (16) and 
AhR activity is induced by suspension in keratinocytes or hepatocytes (25, 26). Moreover, AhR 
localization may be regulated depending on the density of murine fibroblasts or human 
keratinocytes. Here, sparse density favored nuclear AhR localization whereas AhR was found 
predominantly in the cytoplasm at confluence (27, 28). We noticed a reduction in AhR signaling 
upon integrin inhibition that was not restricted to the adherent cell fraction, but was observed in 
the floating cell fraction to a similar extent (Fig. 1E). In addition, similar effects were observed in 
LN-229 or Ha-Cat cells (Fig. 1F, 5C) in which integrin inhibition does not induce detachment or 
cell death nor affects proliferation (data not shown). These data demonstrate that the observed 
alterations in AhR signaling upon integrin inhibition are independent from detachment or cellular 
density.  
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Investigations regarding the mechanism revealed that reduced AhR reporter activity upon 
integrin inhibition is not mediated at the transcriptional level, but results from a reduction of AhR 
total protein levels accompanied by diminished AhR nuclear localization (Fig. 3). In line with 
these findings, a tight control of the AhR pathway at various levels has been described before. 
Beside the regulation of AhR at the transcriptional level which is partially controlled by the drug-
metabolizing CYP enzymes through an autoregulatory feedback loop, AhR activity is controlled 
at the level of nucleo-cytoplasmatic shuttling and dissociation from the molecular chaperones, 
displacement from ARNT by AhR repressor (AhRR), or proteosomal protein degradation (3, 4, 
29, 30). 
Since antagonism of AhR and integrin inhibition both reduce TGF-β signaling (8, 11), and since 
integrin inhibition interferes with AhR signaling, we asked whether integrin inhibition-mediated 
effects on TGF-β signaling are mediated through AhR. Based on this assumption, integrin 
inhibition-mediated effects on TGF-β signaling should be blunted in murine AhR-null 
hepatocytes. Constitutive pSmad2 protein levels were similar in control and AhR-null 
hepatocytes. Indeed, AhR-null cells were less responsive to integrin inhibition-mediated 
reductions in Smad2 phosphorylation demonstrating that AhR plays a role in linking integrins 
and TGF-β signaling. However, the partially remaining effect upon integrin inhibition indicates 
that other regulating mechanisms beside AhR must be involved in controlling TGF-β signaling as 
well as integrin inhibition-mediated alteration of the TGF-β pathway (Fig. 4C). The mouse cells 
used for this analysis detach upon integrin inhibition (data not shown) and detachment may alter 
AhR and TGF-β signaling (11, 25, 26). Accordingly, we used human keratinocytes which do not 
detach upon integrin inhibition as a model to address the influence of cellular detachment. 
Silencing of AhR resulted in dramatically reduced AhR and CYP1A1 mRNA expression and 
integrin inhibition-induced reductions in AhR signaling were abolished in AhRsi cells (Fig. 5A-C). 
The reduced responsiveness to integrin inhibition-mediated effects on TGF-β2 mRNA and 
pSmad2 protein levels in AhRsi cells confirmed that AhR is a central mediator that links integrins 
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and TGF-β signaling. In line with these data, the results obtained by investigation of AhR-null 
astrocytes or LN-308 cells with transiently silenced AhR confirmed the importance of this 
signaling pathway in cells of glial origin, too (Fig. 6). While several studies identified AhR as a 
transcriptional target of the TGF-β pathway (31, 32), we have shown that in our model integrin 
inhibitors regulate AhR at a posttranscriptional level. This is due to the observation that AhR 
mRNA expression was not affected by integrin inhibition while at the same time AhR protein and 
AhR downstream signaling were reduced, paralleled by a reduction in TGF-β signaling (Fig. 5). 
Previous publications have reported conflicting findings on the role of AhR for TGF- expression. 
Reduced but also elevated TGF-β levels upon activation of the AhR pathway have been 
observed in a cell type-specific manner (8, 33-36). Our results suggest that AhR may primarily 
act as a positive regulator of TGF-β signaling, at least in the context of integrin activity. This 
assumption is further corroborated by a striking correlation of αv integrin expression with nuclear 
AhR levels and pSmad2 expression in human glioblastomas in vivo (Fig. 7). The importance of 
αv integrin, AhR and pSmad2 expression for the biology of gliomas has been shown before, as 
their expression correlates with the WHO grade (8, 11, 19). Our data now suggest a close 
interplay between αv integrin, AhR and pSmad2 expression which may cooperate on a 
functional level and contribute to the malignant phenotype of glioblastoma. Previous efforts to 
exploit these targets therapeutically in glioblastoma have been disappointing including a phase 
III trial on the pentapeptide integrin antagonist cilengitide. In addition, the TGF- receptor 
antagonist LY2157299 administered alone or in combination with chemotherapy may not offer a 
breakthrough in glioblastoma therapy (37, 38). Yet, cilengitide may not have had an optimal 
pharmacodynamic and pharmacokinetic profile, and LY2157299 may not have been tolerated at 
doses required to efficiently abrogate TGF-signaling in vivo. The present findings support the 
ongoing search for more potent integrin inhibitors as well as drugs which interfere with the TGF-
 pathway. In summary, we have identified a novel mechanism in which integrin inhibitors 
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interfere with AhR signaling at a posttranscriptional level, ultimately resulting in reduced TGF-β 
signaling. These findings validate integrin inhibition as a promising strategy to block both AhR- 
and TGF--controlled features of malignancy in glioblastoma.    
 
14 
 
Materials and methods 
 
Cells and reagents 
The human long-term cell glioma cell lines (LTC) LN-229 and LN-308 were kindly provided by 
Dr. N. de Tribolet (Lausanne, Switzerland), were recently authenticated by STR profiling and 
tested for mycoplasma contamination. The generation of LN-229 cells overexpressing 
constitutive active AhR (CA-AhR) has been described (8). The glioma initiating cells (GIC) ZH-
161 and S-24 were established from freshly resected tumors, used during the first passages (39) 
and cultured in phenol red-free Neurobasal Medium with B-27 supplement (20 µl/ml), Glutamax 
(10 µl/ml) (Invitrogen, Basel, Switzerland), fibroblast growth factor (FGF)-2, epidermal growth 
factor (EGF) (20 ng/ml each; Peprotech, Rocky Hill, PA) and heparin (32 IE/ml; Ratiopharm, 
Ulm, Germany). Hepatocytes, isolated from wildtype or AhR-null neonatal C57BL/6N  mice and 
immortalized with Simian virus 40, were kindly provided by G. H. Perdew (17) and were grown in 
GIBCO minimum essential medium alpha (Invitrogen), supplemented with 10% fetal calf serum 
(FCS; Gibco Life Technologies, Paisley, UK), 100 U/ml penicillin and 100 µg/ml streptomycin 
(Sigma-Aldrich, St. Louis, MO). Doxycycline-inducible AhR knockdown (HaCaT 4.2) or scramble 
shRNA control cells were generated by lentivirus-mediated transfection (40). The knockdown 
was induced using 2 μg/ml doxycycline (Sigma-Aldrich). AhR-deficient mice (B6.129-AHRtm1Bra/J) 
(7), kindly provided by C. Esser (Düsseldorf, Germany), were crossed on a B6.Cg-Tyrc-2J/J 
background (41) (B6.Cg-Ahrtm1Bra Tyrc-2J) and astrocytes were isolated from AhR-/- or AhR+/- P1 or 
P2 neonatal mice by seeding the cortical cells for mixed glial cultures on poly-L-lysine (2 μg/cm2, 
Sigma-Aldrich)-coated flasks, after cerebral cortices were dissected, freed from the meninges 
and digested with 0.25 % trypsin and 0.1 mg/ml DNase I (Sigma-Aldrich) for 20 min at 37 °C. At 
confluence (d7-d9), cultures were treated with 10 μM cytosine arabinoside (Ara-C, Sigma-
Aldrich) for 5 days. At the end of Ara-C treatment, cultures were less than 2.5 % CD11b+ as 
assessed by flow cytometry (data not shown). For in vitro experiments, the obtained AhR-null 
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astrocytes from homozygous (AhR-/-) mice or control astrocytes from heterozygous (AhR+/) 
B6.Cg-Ahrtm1Bra Tyrc-2J mice, were grown on poly-L-lysine (2 μg/cm2)-coated flasks in Dulbecco's 
Modified Eagle Medium (DMEM; Invitrogen), containing 2 mM L-glutamine (Gibco Life 
Technologies), 100 U/ml penicillin and 100 µg/ml streptomycin, and 10% FCS. Human LTC were 
maintained in DMEM, containing 2 mM L-glutamine (Gibco Life Technologies) and 10% FCS, 
whereas the experiments were carried out in phenol red-free medium without serum, after 
attachment of the cells. Accutase was purchased from Gibco Life Technologies. Cilengitide 
(EMD 121974) was kindly supplied by Merck KGaA (Darmstadt, Germany), GLPG0187 by 
Galapagos NV (Mechelen, Belgium) and the RAD peptide cyclo-(Arg-Ala-Asp-DPhe-Val) was 
obtained from Bachem AG (Bubendorf, Switzerland). CH-223191 was purchased from Merck, 
and 3-methylcholanthrene (3-MC) and doxycycline from Sigma Aldrich. The following antibodies 
were used: phospho-Smad2 (Ser465/467) (clone 138D4) and Smad2 (clone 86F7) were from 
Cell Signaling Technology (Boston, MA), mouse anti-Smad2/3 antibody was from BD 
Biosciences, goat polyclonal antibody to actin from Santa Cruz Biotechnology (Santa Cruz, CA) 
and the mouse monoclonal antibodies to AhR (clone RPT1 for immunoblotting and clone RPT9 
for immunofluorescence) were from Abcam (Cambridge, UK). The antibodies to αv (clone 17E6), 
αvβ3 (clone LM609, MAB1976) and αvβ5 (clone P1F6, MAB1961) were obtained from Merck. 
The siRNA pool targeting AhR or single integrins and the non-targeting control pool were 
purchased from Thermo Scientific Dharmacon (Lafayette, CO) and used at 100 nM. Transient 
lipophilic transfection was performed with Metafectene Pro (Biontex, Martinsried, Germany).  
 
Real-time PCR 
Total RNA was isolated using the NucleoSpin RNA II system from Macherey-Nagel (Düren, 
Germany) and cDNA was prepared using the High Capacity cDNA Reverse Transcription Kit 
from Applied Biosystems (Foster City, CA). Gene expression was measured in an ABI Prism 
7000 Sequence Detection System (Applied Biosystems) using SYBR Green Master Mix from 
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Thermo Fisher Scientific (Waltham, MA) and primers from Microsynth AG (Balgach, Switzerland) 
at optimized concentrations. Glyceraldehyde 3-phosphate dehydrogenase primers have been 
described (42). Primer sequences were as follows: human AhR, forward 5′-
GGCTCAGGTTATCAGTTTATT (NM_001621.3, nt 1537–1557), reverse 5′-
ACTATCATGCCACTTTCTCC-3′ (NM_001621.3, nt 1612–1631), human CYP1A1, forward 5′-
CAGCTGGATGAGAACGCCAAT-3′ (NM_000499.3, nt 999–1019), reverse 5′-
GTGTCAAACCCAGCTCCAAAG (NM_000499.3, nt 1064–1083) ), human TGF-β1, forward 5′-
GCCCTGGACACCAACTATTG-3′ (NM_000660.3, nt 1702–1727), reverse 5′-
CGTGTCCAGGCTCCAAATG-3′ (NM_000660.3, nt 1851–1869), human TGF-β2, forward 5′-
AAGCTTACACTGTCCCTGCTGC-3′ (NM_003238.1, nt 847–868), reverse 5′-
TGTGGAGGTGCCATCAATACCT-3′ (NM_003228.1, nt 934–955), mouse HPRT1, forward 5′-
TTGCTGACCTGCTGGATTAC-3′ (NM_013556.2, nt 370-389), reverse 5′-
TTTATGTCCCCCGTTGACTG-3′ (NM_013556.2, nt 471-490), mouse AhR, forward 5′-
AGCCGGTGCAGAAAACAGTAA-3′ (NM_01346, nt 47-67), reverse 5′-
AGGCGGTCTAACTCTGTGTTC-3′ (NM_01346, nt 126-146), mouse CYP1A1, forward 5′-
CAATGAGTTTGGGGAGGTTACTG-3′ (NM_009992, 675-697), reverse 5′-
CCCTTCTCAAATGTCCTGTAGTG-3′ (NM_009992, 817-839), mouse TGF-β1, forward 5′-
CTCCCGTGGCTTCTAGTGC-3′ (NM_011577.1, 910-928), reverse 5′-
GCCTTAGTTTGGACAGGATCTG-3′ (NM_011577.1, 1021-1042) and mouse TGF-β2, forward 
5′-TCGACATGGATCAGTTTATGCG-3′ (NM_009367.3, 1298-1319), reverse 5′-
CCCTGGTACTGTTGTAGATGGA-3′ (NM_009367.3, 1423-1444). The conditions were 40 
cycles at 95°C/15 s and 60°C/1 min. Standard curves were generated for each gene. Relative 
quantification of gene expression was determined by comparison of threshold values. All results 
were normalized to the house keeping gene and calculated with the ΔCTT method for relative 
quantification (39). 
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Immunoblot analysis 
Whole cell lysates were prepared by lysing cells in radioimmunoprecipitation assay (RIPA) buffer 
(10 mM Tris pH 8.0, 150 mM NaCl, 1% NP-40, 0.5% deoxycholate, 0.1% sodium dodecyl 
sulfate) supplemented with 1x complete inhibitor mix (Roche Diagnostics, Grenzach-Wyhlen, 
Germany) and phosphatase inhibitor cocktails 1 and 2 (Sigma-Aldrich). Fractionated lysates 
were prepared using the NE-PER Nuclear and Cytoplasmic Extraction Kit from Thermo Fisher 
Scientific. Protein levels were analyzed by immunoblot using 30 µg of protein per lane mixed 
with Laemmli buffer containing β-mercaptoethanol and by visualizing protein bands with 
horseradish peroxidase (HRP)-coupled secondary antibodies (Sigma-Aldrich) and enhanced 
chemiluminescence (Perbio, Bonn, Germany). Quantification of the density of protein bands was 
done with ImageJ software (U. S. National Institutes of Health, Bethesda, MD). 
 
Flow cytometry 
For detection of AhR intracellular protein levels, cells were detached with accutase and 
permeabilized using the Fix/Perm Buffer Set (Biolegend, San Diego, CA) followed by incubation 
with anti-human AhR-PE antibody (eBioscience, San Diego, CA) or isotype control, diluted in 
PBS containing 0.5% bovine serum albumin, 2 mM EDTA and 1 mM MgCl2. Intracellular 
expression levels were determined using a CyAn flow cytometer (Beckman Coulter, Nyon, 
Switzerland).  
 
Immunofluorescence 
Immunofluorescence studies were carried out on cytospins (5 x 105 cells/slide). Samples were 
dried for 30 min and fixed in ice-cold methanol:aceton (1:1). AhR staining was performed as 
described (8) and binding specificity was controlled by IgG isotype control (Jackson 
Immunoresearch, Suffolk, UK).  
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Gene reporter assay 
Dual luciferase/renilla assays were performed with co-transfection of 150 ng of the pT81/3 x 
DRE reporter construct, containing  the DRE3 from the CYP enhancer region (43), and 20 ng of 
renilla reniformis-CMV (pRL-CMV) control plasmid (Promega, WI). LN-229 cells were 
transfected with 75 ng of the pT81/3 x DRE reporter construct, 75 ng of the co-plasmid pARNT 
(44) and 20 ng of pRL-CMV. Luciferase activity was normalized to constitutive renilla activity.  
 
TCGA analysis 
Analysis within the TCGA database (http://cancergenome.nih.gov) was done for the 
glioblastoma 540 - MAS5.0 - u133a dataset (n=540) using the module for correlation of 2 genes 
of the R2: microarray analysis and visualization platform (http://r2.amc.nl).  
 
Immunohistochemistry 
Glioblastomas were analyzed on a tissue microarray (TMA). The TMA, kindly provided by Karl 
Frei (Department of Neurosurgery, Zurich), contained tissue of 47 glioblastomas as previously 
described (45). TMA sections were stained using the rabbit monoclonal primary antibody anti-
integrin pan-αv (clone EM01309, 1:10.000), the rabbit polyclonal antibody anti-pSmad2 (clone 
138D4, 1:200) and the mouse monoclonal antibody anti-AhR (clone BHLHE76, 1:200) (8, 46, 
47). The intensity of staining  and the percentage of stained tumor cells were calculated as the 
percentage of weakly stained cells plus the percentage of moderately stained cells multiplied by 
two plus the percentage of strongly stained cells multiplied by three and results were expressed 
as H scores ranging from 0 – 300 (48, 49). A Pearson correlation test was performed using 
Prism 5 (GraphPad Software, San Diego, CA). 
 
Statistical analysis 
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Data are presented as means and SEM for real-time PCR experiments and as means and SD 
for all the other experiments. The experiments shown were repeated at least two to three times. 
Gene reporter assays were performed using at least triplicate wells, whereas real-time PCR was 
performed at least in duplicates. Analysis of significance was performed using a two-tailed 
Student’s t-test (Excel, Microsoft, Redmond, WA) (*p<0.05, **p<0.01). 
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Figure legends 
 
Fig. 1. Integrin inhibition mediates suppression of AhR activity in human glioma cells. A, 
B. LN-308 cells were exposed to RAD (10 µM) or cilengitide (1, 10 or 100 µM) (A), DMSO 
control or GLPG0187 (0.0001, 0.01 or 1 µM) (B) or CH-223191 (10 µM, AhR antagonist) for 24 
h. AhR activity was determined by reporter assays (* p < 0.05; ** p < 0.01, relative to cells 
exposed to RAD (A) or DMSO (B)). C. LN-308 glioma cells were co-cultured with neutralizing 
antibodies at 10 µg/ml to different integrins as indicated or CH-223191 (10 µM). DRE reporter 
activity was analyzed after 24 h (** p < 0.01, relative to cells exposed to isotype control). D. LN-
308 cells were transiently transfected with siRNA oligonucleotides specific for one integrin or a 
control siRNA. AhR activity was determined by reporter assay (* p < 0.05; ** p < 0.01, relative to 
cells transfected with control siRNA). E. LN-308 cells were exposed to RAD, cilengitide (1 µM or 
10 µM), CH-223191 (10 µM) or 3-methylcholanthrene (1.5 µM, 3-MC, AhR agonist) for 6 h. 
Floating and adherent cell fractions were harvested separately F. LN-229 cells were exposed to 
RAD, cilengitide (0.1, 1 or 10 µM), CH-223191 (10 µM) or 3-MC (1.5 µM) for 24 h (right). AhR 
activity was determined by reporter assay (** p < 0.01, relative to cells exposed to RAD). G-J. 
LN-308 cells were exposed to RAD, cilengitide (10 µM), CH-223191 (10 µM) or 3-MC (1.5 µM) 
for 48 h (G) or to DMSO control or GLPG0187 (1 µM) for 12, 24 or 48 h (H). The cells were 
exposed to integrin neutralizing antibodies for 48 h (I) or treated with the indicated integrin 
siRNA oligonucleotides for 48 h (J). CYP1A1 mRNA expression levels were determined by real-
time PCR and normalized to GAPDH. 
 
Fig. 2. Integrin inhibition reduces AhR activity in human GIC. A. ZH-161 or S-24 GIC were 
exposed to RAD, cilengitide (1 or 10 µM) or CH-223191 (10 µM) for 24 h and analyzed for AhR 
activity using reporter assays (* p < 0.05; ** p < 0.01, relative to cells exposed to RAD). B. ZH-
161 or S-24 GIC were exposed to DMSO control, GLPG0187 (0.1 or 1 µM) or CH-223191 (10 
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µM) for 24 h. AhR activity was analyzed by reporter assays (* p < 0.05; ** p < 0.01, relative to 
cells exposed to DMSO). C. ZH-161 or S-24 cells were exposed to RAD or cilengitide (10 µM, 
left), or DMSO or GLPG0187 (10 µM, right) for 72 h. CYP1A1 mRNA expression levels were 
determined by real-time PCR and normalized to GAPDH (* p < 0.05; ** p < 0.01, relative to cells 
exposed to DMSO). 
 
Fig. 3. Integrin inhibition reduces AhR total and nuclear protein levels. A. LN-308 cells 
were exposed to RAD, cilengitide (10 µM), CH-223191 (10 µM) or 3-MC (1.5 µM) for 48 h (top), 
to DMSO control or GLPG0187 (1 µM) for the indicated time points (middle) or were transiently 
transfected with siRNA oligonucleotides specific for one integrin or a control siRNA (bottom). 
AhR mRNA expression levels were determined by real-time PCR after 48 h. B. LN-229 control or 
AhR-CA cells were exposed to RAD or cilengitide (0.1, 1 µM or 10 µM) for 24 h and analyzed for 
AhR activity by reporter assays (bars representing the absolute values, dotted lines representing 
the values relative to RAD; * p < 0.05; ** p < 0.01, relative to cells exposed to RAD; + p < 0.05; ++ 
p < 0.01, relative to control transfected cells) (top). LN-229 control or AhR-CA cells were 
exposed to RAD or cilengitide (10 µM) for 48 h. CYP1A1 mRNA expression levels were 
assessed by real-time PCR (bottom). C. Whole cell protein lysates of LN-308 cells exposed to 
control peptide or cilengitide (1 µM or 10 µM) for 24 h were assessed for AhR, pSmad2 or 
Smad2 protein levels by immunoblot using actin as a loading control. D. Fractionated lysates of 
LN-308 cells exposed to RAD or cilengitide (10 µM) for 24 h were analyzed for AhR protein 
levels, using GAPDH as a control for fractionation and actin as a loading control (top). AhR 
protein levels were normalized to actin (bottom). E. LN-308 cells were exposed to RAD or 
cilengitide (10 µM) for 24 h. AhR expression levels were analyzed by immunofluorescence 
(green). Nuclei were stained with DAPI (blue). 
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Fig. 4: AhR gene silencing abrogates integrin inhibition-mediated effects on TGF-β 
signaling in murine hepatocytes. A. Murine AhR+/+ or AhR-/- hepatocytes were exposed to 
control peptide or cilengitide (10 µM) for 24 h. AhR (top) and CYP1A1 (bottom) mRNA levels 
were assessed by real-time PCR. HPRT1 was used as an internal control (+ p < 0.05; ++ p < 
0.01, relative to control cells). B. Murine AhR+/+ or AhR-/- hepatocytes were treated with RAD or 
increasing concentrations of cilengitide as indicated or CH-223191 for 24 h and DRE reporter 
activity was determined (bars representing the absolute values, dotted lines representing the 
values relative to RAD; * p < 0.05; ** p < 0.01, relative to RAD exposure; ++ p < 0.01, relative to 
control cells). C. Whole cell lysates of AhR+/+ or AhR-/- cells exposed to RAD or cilengitide (10 
µM) for 4 h were analyzed for pSmad2 and Smad2-3 protein levels. Actin was used as a loading 
control.  
 
Fig. 5: AhR silencing interferes with the control of the TGF-β pathway by integrin 
inhibitors in human keratinocytes. A. Human HaCaT control or AhRsi cells were exposed to 
RAD or cilengitide (10 µM) for 48 h. AhR (top) or CYP1A1 (bottom) mRNA expression levels 
were assessed by real-time PCR using GAPDH as an internal control (* p < 0.05, relative to 
RAD exposure; + p < 0.05; ++ p < 0.01, relative to control cells). B. HaCaT control or AhRsi cells 
were exposed to RAD or cilengitide (10 µM) for 24 h. AhR expression levels were assessed by 
flow cytometry upon permeabilization of the cells. C. Human HaCaT control or AhRsi cells were 
treated with RAD or increasing concentrations of cilengitide as indicated for 24 h and DRE 
reporter activity was determined (bars representing absolute values, dotted lines representing 
the values relative to RAD control; ** p < 0.01, relative to cells exposed to RAD). D. HaCaT 
control or AhRsi cells were exposed to RAD or cilengitide (10 µM) for 48 h. TGF-β1 and TGF-β2 
mRNA expression levels were assessed by real-time PCR using GAPDH as an internal control 
(** p < 0.05, relative to RAD exposure; + p < 0.05, relative to control cells). E. Whole cell lysates 
of HaCaT control or AhRsi cells, exposed to RAD or cilengitide (10 µM) for 48 h, were analyzed 
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for AhR, pSmad2 or Smad2 protein levels. Actin was used as a loading control (left). pSmad2 
protein levels were normalized to actin (right).  
 
Fig. 6: AhR silencing interferes with the control of the TGF-β pathway by integrin 
inhibitors in cells of glial origin. A. Control or AhR-null astrocytes were exposed to control 
peptide or cilengitide (10 µM) for 72 h. AhR (top), CYP1A1 (middle) or TGF-β2 (bottom) mRNA 
levels were assessed by real-time PCR. HPRT1 was used as an internal control (* p < 0.05, 
relative to RAD exposure; ++ p < 0.01, relative to control cells). B. LN-308 cells were transiently 
transfected with siRNA specific for AhR or control siRNA. After 24 h, the cells were exposed to 
RAD or cilengitide (10 µM) for 48 h and AhR (top) or CYP1A1 (bottom) mRNA expression levels 
were assessed by real-time PCR using GAPDH as an internal control (++ p < 0.01, relative to 
control cells). C. Whole cell lysates of LN-308 control or AhRsi cells, exposed to RAD or 
cilengitide (10 µM) for 24 h, were analyzed for AhR using actin as a loading control (top). Control 
or AhRsi cells were exposed to RAD, cilengitide (1 or 10 µM) or CH-223131 (10 µM) for 48 h 
and DRE reporter activity was determined (** p < 0.01, relative to cells exposed to RAD; ++ p < 
0.01, relative to control transfectants) (bottom). D. LN-308 control or AhRsi cells were treated as 
in (B) and TGF-β1 and TGF-β2 mRNA expression levels were assessed by real-time PCR using 
GAPDH as an internal control (** p < 0.05, relative to RAD exposure; ++ p < 0.05, relative to 
control cells) (top). Whole cell lysates of LN-308 control or AhRsi cells, exposed to RAD or 
cilengitide (10 µM) for 48 h, were analyzed for pSmad2 or Smad2 protein levels, using actin as a 
loading control (bottom, left). pSmad2 protein levels were normalized to actin (bottom, right). 
 
Fig. 7: αv integrin expression correlates with AhR nuclear levels in vivo. A. Correlation 
analyses of αv integrin with AhR mRNA levels in glioblastoma patients from the TCGA database. 
Two-tailed Pearson test coefficients (r) and significances (p) are indicated. B. Integrin pan-αv, 
pSmad2 or nuclear AhR protein levels were assessed by immunohistochemistry on a 
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glioblastoma tissue microarray (TMA) and correlation analyses were performed. Two-tailed 
Pearson test coefficients (r) and significances (p) are indicated (top). Representative images of a 
tumor with low expression profile of αv integrin, AhR and pSmad2 (left) and a tumor with high 
expression levels of the respective markers (right) are shown and corresponding H scores are 
indicated (scale bar, 100 µm) (bottom).  
 
 
 
0.00
0.05
0.10
0.15
0.20
0.25
0.30
R
A
D
1 
µM
 C
il 
ad
h.
10
 µ
M
 C
il 
ad
h.
1 
µM
 C
il 
flo
at
.
10
 µ
M
 C
il 
flo
at
.
C
H
-2
23
19
1
3-
M
C
R
LU
 [D
R
E]
 
0
0.001
0.002
0.003
0.004
0.005
Ig
G αv
 
α
vβ
3 
α
vβ
5 
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
Fig. 1 
A 
0.00
0.05
0.10
0.15
0.20
control αv si β3 si β5 si β8 si 
R
LU
 [D
R
E]
 
0.00
0.05
0.10
0.15
0.20
R
A
D
1 
µM
 C
il
10
 µ
M
 C
il
10
0 
µM
 C
il
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
E 
0.0
0.5
1.0
1.5
control β3 si β5 si β8 si 
LN-308
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 s
iR
N
A
 
C D 
0.0
0.5
1.0
1.5
2.0
12 24 48
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
 D
M
SO
 c
on
tr
ol
   
h after  exposure to GLPG0187 [1 µM] 
G H 
I 
B 
F 
* 
** 
** 
** 
** ** 
** 
** ** ** 
** ** ** 
* 
** 
* ** 
** 
** 
** 
J 
0.0
1.0
2.0
3.0
4.0
R
A
D C
il
C
H
-2
23
19
1
3-
M
CC
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 R
A
D
 
0.0
0.5
1.0
1.5
IgG αv αvβ3 αvβ5 
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
re
la
tiv
e 
to
 is
ot
yp
e 
co
nt
ro
l 
0.00
0.05
0.10
0.15
0.20
D
M
SO
0.
00
01
 µ
M
 G
LP
G
01
87
0.
01
 µ
M
 G
LP
G
01
87
1 
µM
 G
LP
G
01
87
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
0.00
0.10
0.20
0.30
0.40
R
A
D
0.
1 
µM
 C
il
1 
µM
 C
il
10
 µ
M
 C
il
C
H
-2
23
13
1
R
LU
 [D
R
E]
 
** ** 
** 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
D
M
SO
0.
1 
µM
 G
LP
G
1 
µM
 G
LP
G
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
R
A
D
1 
µM
 C
il
10
 µ
M
 C
il
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
R
A
D
1 
µM
 C
il
10
 µ
M
 C
il
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
Fig. 2 
A 
B 
C 
ZH-161 S-24 
ZH-161 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
D
M
SO
0.
1 
µM
 G
LP
G
1 
µM
 G
LP
G
C
H
-2
23
19
1
R
LU
 [D
R
E]
 
S-24 
** 
** 
* 
** 
* ** 
* ** 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
DMSO GLPG DMSO GLPG
ZH-161 S-24
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 R
A
D
 
* 
** 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
RAD Cil RAD Cil
ZH-161 S-24
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 R
A
D
 
0.0
0.1
0.2
0.3
0.4
0.5
RAD Cil RAD Cil RAD Cil
nuclear cytoplasmic totalA
hR
 p
ro
te
in
 le
ve
ls
 re
la
tiv
e 
to
 A
ct
in
 
Fig. 3 
A 
B 
0.0
0.5
1.0
1.5
control β3 si β5 si β8 si 
LN-308
A
hR
 m
R
N
A
 e
xp
re
ss
io
n 
 re
la
tiv
e 
to
 c
on
tr
ol
 s
iR
N
A
 
0.0
0.5
1.0
1.5
12 24 48
h after exposure to
GLPG0187
A
hR
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 D
M
SO
 c
on
tr
ol
   
0.0
0.5
1.0
1.5
R
A
D C
il
C
H
-2
23
19
1
3-
M
C
A
hR
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 R
A
D
 
E 
RAD 
Cil 
AhR DAPI merge 
nuclear 
R
AD
 
C
il 
R
AD
 
C
il 
cytoplasmic 
AhR 
Actin 
GAPDH 
LN-308 
C 
D 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
LU
 [D
R
E + A
R
N
T] relative to R
A
D
 
LN-229 control LN-229 AhR-CA
0.00
0.05
0.10
0.15
0.20
0.25
0.30
0.35
RAD 0.1 µM Cil 1 µM Cil 10 µM Cil
R
LU
 [D
R
E 
+ 
A
R
N
T]
 
LN-229 control LN-229 AhR-CA
* 
** 
++ 
** 
++ 
+ ++ 
* ** 
* 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
RAD Cil RAD Cil
LN-229 control LN-229  AhR-CA
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 G
A
PD
H
 
AhR 
Actin 
1 
µM
 R
AD
 
10
 µ
M
 R
AD
 
1 
µM
 C
il 
10
 µ
M
 C
il 
LN-308 
pSmad2 
Actin 
Smad2 
Fig. 4 
B 
C 
A 
AhR+/+ 
R
AD
 
C
il 
AhR-/- 
pSmad2 
Actin 
Hepa 
R
AD
 
C
il 
Smad2-3 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
RAD Cil RAD Cil
Hep AhR +/+ Hep AhR -/-
Ah
R
 m
R
N
A 
ex
pr
es
si
on
  
re
la
tiv
e 
to
 A
hR
+/
+  
ce
lls
 (R
AD
) 
++ ++ 
+/+ -/- 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
RAD Cil RAD Cil
Hep AhR +/+ Hep AhR -/-
C
YP
1A
1 
m
R
N
A 
ex
pr
es
si
on
  
re
la
tiv
e 
to
 A
hR
+/
+  
ce
lls
 (R
AD
) 
+ 
+/+ -/- 
0.0
0.5
1.0
1.5
2.0
R
LU
 [D
R
E] relative to R
AD
 
AhR +/+ AhR -/-
0.00
0.05
0.10
0.15
0.20
0.25
R
A
D
0.
1 
µM
 C
il
1 
µM
 C
il
10
 µ
M
 C
il
C
H
-2
23
13
1
3-
M
C
R
LU
 [D
R
E]
 
AhR +/+ AhR -/-
* ** 
** 
++ 
++ ++ ++ 
++ ++ 
+/+ -/- 
+/+ -/- 
Fig. 5 
A 
B 
C 
E 
HaCaT 
control 
R
A
D
 
C
il 
HaCaT  
AhRsi 
R
A
D
 
C
il 
pSmad2 
Actin 
AhR 
Smad2 
0.0
0.2
0.4
0.6
0.8
1.0
RAD Cil RAD Cil
HaCaT control HaCaT AhRsi
pS
m
ad
2 
pr
ot
ei
n 
le
ve
ls
  
re
la
tiv
e 
to
 A
ct
in
 
0.0
0.5
1.0
1.5
RAD Cil RAD Cil
HaCaT control HaCaT AhRsi
A
hR
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
+ + 
0.0
0.5
1.0
1.5
RAD Cil RAD Cil
HaCaT control HaCaT AhRsiC
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
++ ++ 
* 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
RAD Cil RAD Cil
HaCaT control HaCaT AhRsi
SF
I [
A
hR
] 
re
la
tiv
e 
to
 c
on
tr
ol
 
0.0
0.5
1.0
1.5
RAD Cil RAD Cil
HaCaT control HaCaT AhRsi
TG
F-
β
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 to
 c
on
tr
ol
 (R
A
D
) 
TGF-β 
TGF-β 
** 
+ 
2 
1 
D 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
R
LU
 [D
R
E]  
relative to R
A
D
 
Ha-Cat control Ha-Cat AhRsi
0
0.02
0.04
0.06
0.08
RAD 1 µM Cil 10 µM Cil
R
LU
 [D
R
E]
 
Ha-Cat control Ha-Cat AhRsi
H 
a H
a 
CaT trol 
** 
H 
a a T control 
HaC T AhRsi 
Ha T AhRsi 
Fig. 6 
D 
0.0
0.5
1.0
1.5
RAD Cil RAD Cil
control AhRsi
A
hR
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
++ ++ 
0.0
0.5
1.0
1.5
RAD Cil RAD Cil
control AhRsiC
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
0.0
0.5
1.0
1.5
RAD Cil RAD Cil
control AhRsi
TG
F-
β
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
TGF-β 
TGF-β 
** ++ 
2 
1 
B 
C 
control 
R
A
D
 
C
il 
AhRsi 
R
A
D
 
C
il 
Actin 
AhR 
LN-308 
control 
R
A
D
 
C
il 
AhRsi 
R
A
D
 
C
il 
pSmad2 
Actin 
Smad2 
LN-308 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
RAD Cil RAD Cil
control AhRsi
LN-308
pS
m
ad
2 
pr
ot
ei
n 
le
ve
ls
  
re
la
tiv
e 
to
 A
ct
in
 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
R
A
D
1 
µM
 C
il
10
 µ
M
 C
il
C
H
-2
23
13
1
R
LU
 [D
R
E]
 
LN-308 control
LN-308 AhRsi
** 
** 
++ ++ ++ 
++ 
** 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
RAD Cil RAD Cil
control AhR-null
Astrocytes
A
hR
 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
++ ++ 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
RAD Cil RAD Cil
control AhR-null
Astrocytes
C
YP
1A
1 
m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
* 
0
0.2
0.4
0.6
0.8
1
1.2
RAD Cil RAD Cil
control AhR-null
Astrocytes
TG
F-
β
2 m
R
N
A
 e
xp
re
ss
io
n 
 
re
la
tiv
e 
to
 c
on
tr
ol
 c
el
ls
 (R
A
D
) 
++ * 
A 
Fig. 7 
A 
B 
2
4
6
8
10
12
7 8 9 10 11 12
2l
og
 o
f A
hR
 
2log of αv 
r = 0.15 
p < 0.001 
0
100
200
300
0 100 200 300 400
Ah
R
 H
 s
co
re
 
αv H score 
r = 0.32 
p < 0.05 
0
100
200
300
0 100 200 300 400
pS
m
ad
2 
H
 s
co
re
 
αv H score 
r = 0.38 
p < 0.01 
AhR 
pSmad2 
αv 
Patient 1: low Patient 2: high 
H score 
175 
H score 
285 
H score 
95 
H score 
95 
H score 
200 
H score 
285 
